Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study

被引:50
作者
Ishihara, Hisamitsu [1 ]
Yamaguchi, Susumu [2 ]
Nakao, Ikko [2 ]
Okitsu, Akira [2 ]
Asahina, Seitaro [2 ]
机构
[1] Nihon Univ, Sch Med, Div Diabet & Metab Dis, Itabashi Ku, 30-1 Oyaguchikami Cho, Tokyo 1738610, Japan
[2] Astellas Pharma Inc, Tokyo, Japan
关键词
type; 2; diabetes; insulin therapy; SGLT2; inhibitor; DPP-4; GLUCOSE COTRANSPORTER 2; GLYCEMIC CONTROL; INHIBITOR; DAPAGLIFLOZIN; SENSITIVITY; SITAGLIPTIN;
D O I
10.1111/dom.12745
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimsTo examine the efficacy and safety of add-on ipragliflozin in Japanese patients with type 2 diabetes in the early stage of insulin therapy. MethodsPatients treated with insulin (bolus component <30% of total daily dose) with/without a dipeptidyl peptidase-4 (DPP-4) inhibitor were randomized to receive placebo (n=87) or ipragliflozin (n=175) for 16weeks. The primary endpoint was the change in glycated haemoglobin (HbA1c) from baseline. Secondary endpoints included changes in fasting plasma glucose (FPG) and metabolic hormones. Safety endpoints were also examined. ResultsThe changes in HbA1c were 0.27% and -0.79% (2.9 and -8.7 mmol/mol) in the placebo and ipragliflozin groups, respectively (baseline: 8.62% vs 8.67% [70.8 vs 71.2 mmol/mol]), corresponding to an adjusted mean difference of -1.07% (95% confidence interval -1.24, -0.91) or -11.7 mmol/mol (-13.5, -9.9), p<.001. Ipragliflozin reduced FPG and serum C-peptide levels and body weight (all p<.001), and increased serum adiponectin levels (p=.022). There was a statistically significant interaction for use/non-use of a DPP-4 inhibitorxtreatment group for the change in HbA1c (p=.042). Hypoglycaemia was the only treatment-related adverse event reported in >5% of patients (14.9% vs 29.1%). Events consistent with urinary tract infection (placebo 1.1% vs ipragliflozin 2.3%) or genital infection (0.0% and 4.0%, respectively) occurred in <5% of patients. ConclusionIpragliflozin was well tolerated and effective in insulin-treated patients, especially when used with a DPP-4 inhibitor.
引用
收藏
页码:1207 / 1216
页数:10
相关论文
共 19 条
  • [1] Effects of Combining Linagliptin Treatment with BI-38335, A Novel SGLT2 Inhibitor, on Pancreatic Islet Function and Inflammation in db/db Mice
    Chen, L.
    Klein, T.
    Leung, P. S.
    [J]. CURRENT MOLECULAR MEDICINE, 2012, 12 (08) : 995 - 1004
  • [2] Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
    Ferrannini, Ele
    Muscelli, Elza
    Frascerra, Silvia
    Baldi, Simona
    Mari, Andrea
    Heise, Tim
    Broedl, Uli C.
    Woerle, Hans-Juergen
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (02) : 499 - 508
  • [3] Effects of Obesity and Diabetes on α- and β-Cell Mass in Surgically Resected Human Pancreas
    Inaishi, Jun
    Saisho, Yoshifumi
    Sato, Seiji
    Kou, Kinsei
    Murakami, Rie
    Watanabe, Yuusuke
    Kitago, Minoru
    Kitagawa, Yuko
    Yamada, Taketo
    Itoh, Hiroshi
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (07) : 2874 - 2882
  • [4] Jurczak MJ, 2011, DIABETES, V60, P890, DOI 10.2337/db10-1328
  • [5] A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long-Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) study
    Kashiwagi, A.
    Takahashi, H.
    Ishikawa, H.
    Yoshida, S.
    Kazuta, K.
    Utsuno, A.
    Ueyama, E.
    [J]. DIABETES OBESITY & METABOLISM, 2015, 17 (02) : 152 - 160
  • [6] Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study
    Kashiwagi, A.
    Kazuta, K.
    Goto, K.
    Yoshida, S.
    Ueyama, E.
    Utsuno, A.
    [J]. DIABETES OBESITY & METABOLISM, 2015, 17 (03) : 304 - 308
  • [7] Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus
    Kashiwagi, Atsunori
    Kazuta, Kenichi
    Yoshida, Satoshi
    Nagase, Itsuro
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2014, 5 (04) : 382 - 391
  • [8] Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus
    Katsuno, Tomoyuki
    Ikeda, Hiroki
    Ida, Kenichi
    Miyagawa, Jun-ichiro
    Namba, Mitsuyoshi
    [J]. ENDOCRINE JOURNAL, 2013, 60 (06) : 733 - 742
  • [9] Benefits of timely basal insulin control in patients with type 2 diabetes
    Lovre, Dragana
    Fonseca, Vivian
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2015, 29 (02) : 295 - 301
  • [10] Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
    Merovci, Aurora
    Solis-Herrera, Carolina
    Daniele, Giuseppe
    Eldor, Roy
    Fiorentino, Teresa Vanessa
    Tripathy, Devjit
    Xiong, Juan
    Perez, Zandra
    Norton, Luke
    Abdul-Ghani, Muhammad A.
    DeFronzo, Ralph A.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (02) : 509 - 514